Surrey Heartlands

Joint Formulary & PAD

Sacubitril/valsartan - Heart failure

You are here : Home > Formulary Search > Sacubitril/valsartan - Heart failure

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
SPC
Restrictions / Comments :
Important

Specialist team to initiate, up titrate and stabilise onto the maximum tolerated dose (for a minimum of 4 weeks), prior to transfer of care to primary care.

 

Status 2

Non Formulary
Formulations :
  • Granules
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
NFD1
SPC
Restrictions / Comments :
Important

Only licensed for use in children.

Documentation

Evidence Review
Sacubitril Valsartan - Change in Traffic Light classification - June 2025.pdf
Webpage
NICE TA388 - Sacubitril Valsartan in Chronic Heart Failure

PAD Profile

ChemicalSubstance :
Sacubitril/valsartan
Indication :
Heart failure
Group Name :
Keywords :
Sacubitril, CHF, valsartan, neprilysin inhibitor, angiotensin receptor antagonist
Brand Names Include :
Entresto
Important Information :
Do not co-administer with an ACEi or ARB due to risk of angioedema.
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Heart failure
Supporting Documents :
2
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Sacubitril/valsartan is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Heart failure.

Committee Recommendations (1)

04 Jun 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a change in traffic light status to BLUE (with specialist initiation) for sacubitril valsartan for the treatment of Heart Failure, with prescribing by the specialist team to initiate, up titrate and stabilise onto the maximum tolerated dose (for a minimum of 4 weeks), prior to transfer of care to primary care.